Results 151 to 160 of about 843,778 (210)

Identification of 6-Anilino Imidazo[4,5-c]pyridin-2-ones as Selective DNA-Dependent Protein Kinase Inhibitors and Their Application as Radiosensitizers. [PDF]

open access: yesJ Med Chem
Hong CR   +11 more
europepmc   +1 more source

Promises of Protein Kinase Inhibitors in Recalcitrant Small-Cell Lung Cancer: Recent Scenario and Future Possibilities. [PDF]

open access: yesCancers (Basel)
Tiwari A   +7 more
europepmc   +1 more source

Salt-inducible kinases (SIKs) regulate TGFβ-mediated transcriptional and apoptotic responses [PDF]

open access: yes, 2020
A Rojas-Fernandez   +63 more
core   +2 more sources

Targeting the trypanosome kinetochore with CLK1 protein kinase inhibitors. [PDF]

open access: yesNat Microbiol, 2020
Saldivia M   +22 more
europepmc   +1 more source

Non-kinase targets of protein kinase inhibitors

Nature Reviews Drug Discovery, 2017
Kinome-wide profiling platforms have comprehensively identified the relevant kinases that are targeted by numerous protein kinase inhibitors. However, recent projects have begun to discover non-kinase targets of kinase inhibitors. These non-kinase targets can contribute to the desired or undesired activities of inhibitors, or act as silent bystanders ...
Lenka Munoz
openaire   +5 more sources

Irreversible Protein Kinase Inhibitors

Current Medicinal Chemistry, 2011
Targeting cancer with small molecule irreversible inhibitors of kinases represents an emerging challenge in drug discovery. Irreversible inhibitors bind to kinase active site in a covalent and irreversible form, most frequently by reacting with a nucleophilic cysteine residue, located near the ATP binding pocket.
GARUTI, LAURA   +2 more
openaire   +4 more sources

Protein kinase inhibitors in melanoma

Expert Opinion on Pharmacotherapy, 2013
The most commonly mutated oncogene identified to date in melanoma is BRAF (∼ 50%), an upstream mediator of the mitogen-activated protein kinase (MAPK) pathway. Recently, BRAF-kinase inhibitors as well as MEK-kinase inhibitors were introduced into the clinics.Substantial Phase II and III clinical trials were searched in patients with advanced melanoma ...
Claus Garbe   +2 more
openaire   +3 more sources

Inhibitors of protein kinases and phosphatases

Trends in Biochemical Sciences, 1994
Inhibitors of eukaryotic protein kinases and phosphatases are a chemically diverse array of natural and synthetic compounds, including medicines, potions and poisons. These substances are valuable pharmacological probes and affinity ligands for the kinases and phosphatases of signalling pathways, enhancing our knowledge of the cellular effects of the ...
MacKintosh, Carol, MacKintosh, Robert W.
openaire   +4 more sources

Home - About - Disclaimer - Privacy